Shanvac-B (hepatitis b vaccine): Uses, Dosage & Side Effects

What it's for (Indications)

Hepatitis B vaccine is indicated for active immunization against infection caused by all known subtypes of hepatitis B virus (HBV).
It is primarily recommended for universal immunization of infants and children, and for adolescents and adults at increased risk of exposure to HBV.
Risk groups include healthcare workers, public safety personnel with occupational exposure, hemodialysis patients, residents and staff of institutions for developmentally disabled persons, international travelers to regions with high HBV endemicity, individuals with multiple sexual partners, men who have sex with men, injection drug users, household contacts and sexual partners of HBV carriers, and individuals with chronic liver disease or HIV infection.
Vaccination is also recommended for all unvaccinated adults aged 19-59 years and for adults aged ≥60 years with risk factors for hepatitis B infection.
This comprehensive preventative strategy aims to reduce the global burden of acute and chronic hepatitis B disease, including cirrhosis and hepatocellular carcinoma, by establishing protective immunity prior to exposure.

Dosage Information

Type	Guideline
Standard	The dosage regimen for hepatitis B vaccine varies depending on the specific product, age of the recipient, and underlying health conditions. For most standard adult formulations, a three-dose intramuscular (IM) series is administered. Typically, the first dose is given at a chosen date, the second dose one month after the first, and the third dose six months after the first (0, 1, 6-month schedule). For infants born to HBsAg-negative mothers, the first dose is usually given at birth, often along with hepatitis B immune globulin, followed by subsequent doses according to the recommended childhood immunization schedule. Accelerated schedules may be used in certain situations, such as impending travel to endemic areas or post-exposure prophylaxis. Specific formulations, like those for dialysis patients, may involve higher antigen concentrations or additional doses to ensure an adequate immune response due to their often-compromised immune systems. It is crucial to adhere strictly to the recommended schedule for optimal seroprotection. Booster doses are generally not routinely recommended for immunocompetent individuals who have completed the primary series and responded adequately, although this may be reconsidered for specific high-risk populations or in cases of declining antibody levels over time, guided by serologic testing.

Type

Guideline

Standard

The dosage regimen for hepatitis B vaccine varies depending on the specific product, age of the recipient, and underlying health conditions. For most standard adult formulations, a three-dose intramuscular (IM) series is administered. Typically, the first dose is given at a chosen date, the second dose one month after the first, and the third dose six months after the first (0, 1, 6-month schedule). For infants born to HBsAg-negative mothers, the first dose is usually given at birth, often along with hepatitis B immune globulin, followed by subsequent doses according to the recommended childhood immunization schedule. Accelerated schedules may be used in certain situations, such as impending travel to endemic areas or post-exposure prophylaxis. Specific formulations, like those for dialysis patients, may involve higher antigen concentrations or additional doses to ensure an adequate immune response due to their often-compromised immune systems. It is crucial to adhere strictly to the recommended schedule for optimal seroprotection. Booster doses are generally not routinely recommended for immunocompetent individuals who have completed the primary series and responded adequately, although this may be reconsidered for specific high-risk populations or in cases of declining antibody levels over time, guided by serologic testing.

Safety & Warnings

Common Side Effects

The hepatitis B vaccine is generally well-tolerated, with most adverse reactions being mild and self-limiting.
The most common side effects reported are local reactions at the injection site, including soreness, pain, tenderness, induration, or erythema.
These local reactions typically resolve within 1-2 days without intervention.
Systemic reactions, though less frequent, may include low-grade fever (temperature above 37.
5°C), headache, malaise, fatigue, nausea, diarrhea, dizziness, pharyngitis, or upper respiratory tract infections.
These systemic symptoms are usually mild and transient.
More rarely, hypersensitivity reactions, including urticaria, rash, or pruritus, have been observed.
Serious adverse events are exceedingly rare but can include anaphylaxis, a life-threatening allergic reaction, which occurs in approximately 1 per million doses.
Other very rare neurological events, such as Guillain-Barré syndrome, multiple sclerosis exacerbation, or optic neuritis, have been reported in temporal association with vaccination, though a definitive causal relationship has not been established in most cases.
Healthcare providers should be prepared to manage anaphylaxis following vaccination.
Patients should be advised to report any unusual or severe symptoms post-vaccination to their healthcare provider for appropriate assessment.

Serious Warnings

Black Box Warning: As of current medical understanding and regulatory guidelines, there is no formal FDA-mandated 'Black Box Warning' specifically assigned to hepatitis B vaccines. However, it is crucial to recognize and manage potential serious risks, which, though rare, warrant significant attention. Therefore, this section will outline 'Serious Warnings' associated with hepatitis B vaccine administration. **SERIOUS WARNINGS:** 1. **Anaphylaxis and Severe Hypersensitivity Reactions:** While exceedingly rare, severe allergic reactions, including life-threatening anaphylaxis, can occur following administration of hepatitis B vaccine. This can manifest as generalized urticaria, angioedema, bronchospasm, laryngeal edema, hypotension, or shock. Healthcare providers must ensure that appropriate medical treatment, including epinephrine, antihistamines, and corticosteroids, is immediately available for emergency use in the event of an anaphylactic reaction. Recipients should be observed for a minimum of 15-20 minutes post-vaccination to monitor for immediate reactions. Individuals with a known history of severe allergic reaction to any component of the vaccine, particularly yeast protein (if applicable to the specific vaccine formulation), or to a previous dose of any hepatitis B vaccine, should not receive further doses. 2. **Syncope (Fainting) and Related Injuries:** Syncope, commonly known as fainting, can occur following the administration of injectable vaccines, including the hepatitis B vaccine, particularly in adolescents and young adults. This vasovagal response can lead to transient cerebral hypoperfusion and loss of consciousness. Fainting episodes may result in falls and subsequent injuries, such as head trauma, lacerations, or fractures. To mitigate this risk, healthcare providers should take precautions by having vaccine recipients sit or lie down during the vaccination process and for a period of at least 15 minutes after administration. Observing the patient for signs of syncope and providing appropriate support can help prevent serious injury. Counseling patients about this possibility beforehand can also be beneficial. 3. **Risk in Immunocompromised Individuals:** Immunocompromised persons, including those receiving immunosuppressive therapy (e.g., chemotherapy, high-dose corticosteroids), individuals with HIV infection, or those with other immune-compromising conditions, may have a diminished immune response to the hepatitis B vaccine. This may result in lower seroconversion rates and lower antibody titers compared to immunocompetent individuals, potentially leading to inadequate protection. In such cases, higher doses, additional doses, or post-vaccination serologic testing may be required to confirm adequate protective antibody levels and adjust the vaccination strategy accordingly. The vaccine may also be less effective if administered during a period of severe immunosuppression. 4. **Vaccine Limitations and Pre-existing Infection:** Hepatitis B vaccine will not prevent infection caused by other hepatitis viruses (e.g., hepatitis A, C, D, E) or other pathogens that cause liver inflammation. Furthermore, the vaccine may not protect all individuals who receive it, especially if they are already infected with HBV at the time of vaccination (either acutely or chronically) or if they do not complete the full vaccination series as recommended. The vaccine is ineffective in preventing chronic HBV infection in individuals who are already acutely infected. Therefore, pre-vaccination screening for HBV infection status may be considered in certain high-risk populations to ensure appropriate management and prevent unnecessary vaccination in already infected individuals.
Prior to administration, healthcare providers should assess the recipient's medical history, including any history of allergic reactions to vaccine components or previous doses.
Epinephrine and other appropriate medical treatment should be immediately available for use in case of an acute anaphylactic reaction.
Vaccination should be postponed in individuals with moderate or severe acute illness, including fever, to avoid confounding any vaccine-related adverse events with symptoms of their underlying illness.
However, minor illnesses with or without low-grade fever are generally not contraindications and vaccination can proceed.
The vaccine should be administered with caution to individuals with compromised immune systems, such as those with HIV infection, malignancy, or who are receiving immunosuppressive therapy, as their immune response to the vaccine may be diminished, potentially requiring higher antigen concentrations, additional doses, or post-vaccination serologic testing to confirm protective antibody levels.
As with any vaccine, hepatitis B vaccine may not protect all individuals.
Efficacy depends on several factors, including the recipient's immune status and adherence to the full vaccination schedule.
There is a theoretical risk of syncope (fainting) following injection, particularly in adolescents and young adults, so appropriate precautions should be taken to prevent injury from falls.

How it Works (Mechanism of Action)

The hepatitis B vaccine is a recombinant vaccine, meaning it is produced using genetic engineering technology and does not contain live virus particles or whole inactivated virus. The vaccine consists of purified hepatitis B surface antigen (HBsAg), which is typically produced in yeast cells (Saccharomyces cerevisiae) or mammalian cells. Upon intramuscular injection, the HBsAg acts as a potent antigen, stimulating the recipient's immune system to mount a specific immune response. This response primarily involves the production of anti-HBs antibodies (antibodies against the hepatitis B surface antigen). These antibodies are critical for providing active immunity and protection against future hepatitis B virus infection. When an immunized individual is subsequently exposed to the actual hepatitis B virus, these pre-existing anti-HBs antibodies can bind to the viral HBsAg, effectively neutralizing the virus and preventing it from infecting liver cells. The vaccine induces both humoral immunity (antibody production) and cellular immunity, leading to long-term immunological memory. This memory allows for a rapid and robust antibody response upon re-exposure, effectively preventing active infection and the development of chronic hepatitis B disease, cirrhosis, and hepatocellular carcinoma. The production process ensures that the vaccine is non-infectious and cannot cause hepatitis B disease.